Class I (most serious) Drug D-0625-2026 Ongoing

An antiseptic meant to prevent infection was not sterile — records are published a week at a time (BD ChloraPrep)

CareFusion 213, LLC Reported Jul 1, 2026

The U.S. FDA classified 178,000 applicators of the skin antiseptic "BD ChloraPrep FREPP Clear" from CareFusion 213, a BD subsidiary, as Class I — its most serious category — for non-sterility due to the mold Aspergillus penicillioides and for a lack of assurance of sterility from wrinkles in the paper lidding that may breach the seal.

Recall overview (primary data)

  • ClassificationClass I (most serious)
  • Product typeDrug
  • Recalling firmCareFusion 213, LLC
  • ReasonNon-Sterility: Due to presence of Aspergillus penicillioides. And Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may breach the seal area.
  • DistributionNationwide inthe USA, as well as other foreign distribution.
  • Recall initiated2026-05-28

Key points

  • Recall number D-0625-2026; FDA Class I, the most serious category; status Ongoing.
  • The product is the skin antiseptic "BD ChloraPrep FREPP Clear" (2% chlorhexidine gluconate, 70% isopropyl alcohol), 1.5 mL applicator, 20 per pack, NDC 54365-400-30.
  • Two reasons: non-sterility from the presence of Aspergillus penicillioides, and lack of assurance of sterility from wrinkles in the paper lidding that may breach the seal.
  • Quantity 178,000 applicators; distributed nationwide in the USA and to other foreign markets.
  • Voluntary, firm-initiated. Initiated 2026-05-28; reported 2026-07-01.
  • By report date the 1,408 FDA recall records this site holds as of 2026-09-01 fall on just 19 days, a consequence of weekly batch publication.

1When the product that prevents infection is itself contaminated

This product is an applicator for disinfecting skin before an injection or an operation. Combining chlorhexidine gluconate with isopropyl alcohol, it is meant to reduce bacteria on the skin and prevent infection associated with a procedure. What this recall describes is that the product itself lacked sterility.

When the thing used to prevent infection is contaminated, a moment that would normally be protected becomes a moment of exposure — and by the nature of its use, that moment comes immediately before the skin barrier is crossed.

2Two reasons stated side by side

The FDA record lists two reasons. One is non-sterility due to the presence of a mold, Aspergillus penicillioides. The other is a lack of assurance of sterility, because wrinkles in the paper lidding may breach the seal area. The first is contamination actually detected; the second is the absence of confidence that sterility has been maintained. For sterile products these are treated as separate grounds for failure.

3178,000 applicators, including foreign markets

The quantity is 178,000 applicators, distributed nationwide in the United States as well as to other foreign markets. Skin antiseptics are consumables used routinely in many procedures, so they disperse widely as stock across hospitals and clinics. A single-use applicator tends to sit unopened on shelves for long periods, which makes it likely that a substantial number remain in the field when the recall notice arrives.

4The records are published a week at a time

By report date, the 1,408 FDA recall records this site holds as of 2026-09-01 fall on just 19 days. The heaviest is 2026-06-10 with 147, followed by 2026-06-24 with 142 and 2026-07-08 with 129.

2026-06-10147 / 1408
2026-06-24142 / 1408
2026-07-08129 / 1408

Recalls are not clustering on particular days. The FDA publishes them a week at a time, so the dates in the record bunch onto a handful of days. A spike in one week reflects the rhythm of publication, not a surge of problems that week.

Why it matters

A recall of a consumable that underpins infection control affects hospital operations rather than a single procedure. Securing substitutes, physically quarantining affected lots, and checking the impact on scheduled procedures all have to proceed at once, and the ability to query stock by NDC and lot sets the pace. On the manufacturing side, the case shows that sterility assurance depends not only on microbial testing but also on the integrity of the package seal.

FAQ

What is this product used for?
It is an applicator for disinfecting skin before an injection or an operation, combining chlorhexidine gluconate with isopropyl alcohol.
Why are there two reasons?
One is non-sterility from a mold actually detected; the other is that wrinkles in the packaging lidding may breach the seal, leaving no assurance that sterility was maintained. For sterile products these are separate grounds for failure.
How are affected units identified?
By querying inventory using the NDC (54365-400-30) and lot number. Actual response should follow the FDA official recall information and the manufacturer notices.

Sources (primary)

Source: openFDA (U.S. FDA, CC0 public domain). Data is provided as-is and must not be used for medical decisions. Verify the latest and exact details with the official FDA recall information. This site is not endorsed or certified by the U.S. FDA.

#FDA#Recall#Class I#Drug#Antiseptic#Sterility#Infection control
Disclaimer: This site independently summarizes and classifies information based on official data sources. Always verify the latest and accurate information with the official sources. Content on finance, health, legal, and security is information, not advice. This site is not an official website of the U.S. government.